pharma Β· Cystic Fibrosis Β· Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) patent portfolio β 991 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
Vertex Pharmaceuticals (Australia) patents
991 pharmaceutical patents indexed for Vertex Pharmaceuticals (Australia). 63 expire within 24 months.
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months β use filters for patent-cliff planning.
Patent portfolio
-
US 7745629
Bicyclic derivatives as modulators of ion channels
granted -
US 7741321
Modulators of ATP-binding cassette transporters
granted -
US 7737151
Pyrazine kinase inhibitors
granted -
US 7728017
Inhibitors of c-Met and uses thereof
granted -
US 7727992
Gyrase inhibitors and uses thereof
granted -
US 7718658
Quinazolines useful as modulators of ion channels
granted -
US 7713983
Quinazolines useful as modulators of ion channels
granted -
US 7705002
Biaryls useful as modulators of ion channels
granted -
US 7705031
Benzimidazoles useful as modulators of ion channels
granted -
US 7700609
Compositions useful as inhibitors of protein kinases
granted -
US 7696201
Modulators of muscarinic receptors
granted -
US 7691853
Pyrazole compounds useful as protein kinase inhibitors
granted -
US 7691902
Modulators of ATP-binding cassette transporters
granted -
US 7691885
Pyridones useful as inhibitors of kinases
granted -
US 7683066
Isoquinolines useful as modulators of ion channels
granted -
US 7683033
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
granted -
US 7683065
Pyridines useful as modulators of ion channels
granted -
US 7683083
Biphenyl derivatives as modulators of voltage gated ion channels
granted -
US 7678802
Quinazolines useful as modulators of ion channels
granted -
US 7671221
Modulators of ATP-Binding Cassette transporters
granted -
US 7666647
Inhibitors of GSK-3 and crystal structures of GSK-3Ξ² protein and protein complexes
granted -
US 7659268
Modulators of ATP-binding cassette transporters
granted -
US 7659309
Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
granted -
US 7659283
Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
granted -
US 7652135
Compositions useful as inhibitors of protein kinases
granted -
US 7652153
Caspase inhibitors and uses thereof
granted -
US 7645789
Indole derivatives as CFTR modulators
granted -
US 7645775
Triazoles useful as inhibitors of protein kinases
granted -
US 7625913
Pyrazole compounds useful as protein kinase inhibitors
granted -
US 7622463
Dihydrodiazepines useful as inhibitors of protein kinases
granted -
US 7612091
Caspase inhibitors and uses thereof
granted -
US 7612065
Inhibitors of c-JUN N-terminal kinases (JNK)
granted -
US 7608632
Sulfonamide inhibitors of aspartyl protease
granted -
US 7605270
Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
granted -
US 7605174
Indane derivatives as modulators of ion channels
granted -
US 7601718
Compositions useful as inhibitors of protein kinases
granted -
US 7598412
Modulators of ATP-binding cassette transporters
granted -
US 7598245
Aminotriazole compounds useful as inhibitors of protein kinases
granted -
US 7598277
Inhibitors of p38
granted -
US 7592340
Quinoxalines useful as inhibitors of protein kinases
granted -
US 7592368
Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
granted -
US 7589214
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
granted -
US 7582641
Gyrase inhibitors and uses thereof
granted -
US 7569591
Gyrase inhibitors and uses thereof
granted -
US 7569604
Heterocyclic derivatives for modulation of calcium channels
granted -
US 7563795
Phenyl-piperazine derivatives as modulators of muscarinic receptors
granted -
US 7557106
Substituted pyrimidines useful as protein kinase inhibitors
granted -
US 7553852
Caspase inhibitors and uses thereof
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.